Jiangsu (SH:688426) Tong Hua Shun Cai Bao·2025-04-29 08:13Financial Performance - The company reported a basic earnings per share of -0.2100 yuan for Q1 2025, an improvement of 19.23% compared to -0.2600 yuan in Q1 2024, but a decline from 0.0400 yuan in Q1 2023 [1] - The net profit for Q1 2025 was -0.23 billion yuan, showing a 20.69% improvement from -0.29 billion yuan in Q1 2024, but a decrease from 0.04 billion yuan in Q1 2023 [1] - The operating revenue increased by 48.28% to 0.43 billion yuan in Q1 2025 from 0.29 billion yuan in Q1 2024, but decreased from 0.77 billion yuan in Q1 2023 [1] - The net asset return rate was -1.57% in Q1 2025, an improvement from -1.76% in Q1 2024, but a decline from 0.23% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 13.2036 million shares, accounting for 34.75% of the circulating shares, with a decrease of 357,300 shares compared to the previous period [2] - The largest shareholder, Rongtong Health Industry Flexible Allocation Mixed A/B, holds 3.7612 million shares, representing 9.90% of the total share capital, with an increase of 1.7612 million shares [3] - Notable exits from the top ten shareholders include Li Yizheng and CITIGROUP GLOBAL MARKETS LIMITED, who held 1.4444 million shares (3.80%) and 1.2478 million shares (3.28%) respectively [3] Dividend Policy - The company has announced that it will not distribute or transfer any dividends this time [4]